The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Anisamide‐targeted stealth liposomes: A potent carrier for targeting doxorubicin to human prostate cancer cells
Abstract
Certain human malignancies including prostate cancer overexpress sigma receptor, a membrane bound protein that binds haloperidol and various other neuroleptics with high affinity. An anisamide derivatized ligand possesses high affinity for sigma receptors and we hypothesized that its incorporation into the liposomes encapsulating doxorubicin (DOX) can specifically target and deliver the drug to prostate cancer cells that overexpress sigma receptors. A polyethylene glycol phospholipid was derivatized with an anisamide ligand, which was then incorporated into the DOX‐loaded liposome. The resulting anisamide‐conjugated liposomal DOX showed significantly higher toxicity to DU‐145 cells than non‐targeted liposomal DOX, the IC50 being 1.8 μM and 14 μM respectively. The cytotoxicity of the targeted liposomal DOX, however, was significantly blocked by haloperidol, suggesting that the enhanced cytotoxicity was specifically mediated by the sigma receptors. Fluorescence imaging studies after intravenous (i.v.) administration showed that incorporation of anisamide into liposomes significantly improved their accumulation into the tumor. A weekly injection of the targeted liposomal DOX for 4 weeks at a dose of 7.5 mg/kg led to a significant growth inhibition of established DU‐145 tumor in nude mice with minimal toxicity. Free DOX was effective, but associated with significant toxicities. The present study is the first to demonstrate the use of small molecular weight ligand for mediating efficient targeting of liposomal drugs to sigma receptor expressing prostate cancer cells both in vitro and in vivo. © 2004 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes
Klibanov, A. L., Maruyama, K., Torchilin, V. P., & Huang, L. (1990) · FEBS Letters · doi:10.1016/0014-5793(90)81016-h · Cited by 2,027
Self-citationSigma receptors: biology and function.
Walker, J. M., Bowen, W. D., Walker, F. O., Matsumoto, R. R., De Costa, B., & Rice, K. C. (1990) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)00047-x · Cited by 825
Sigma-1 and sigma-2 receptors are expressed in a wide variety of human and rodent tumor cell lines.
Vilner, B. J., John, C. S., & Bowen, W. D. (1995) · PubMed · Cited by 482
Goren, D., Horowitz, A. T., Tzemach, D., Tarshish, M., Zalipsky, S., & Gabizón, A. (2000) · PubMed · Cited by 468
Hellewell, S. B., Bruce, A., Feinstein, G., Orringer, J., Williams, W., & Bowen, W. D. (1994) · European Journal of Pharmacology: Molecular Pharmacology · doi:10.1016/0922-4106(94)90115-5 · Cited by 390
Uster, P. S., Allen, T. M., Daniel, B. E., Mendez, C. J., Newman, M. S., & Zhu, G. Z. (1996) · FEBS Letters · doi:10.1016/0014-5793(96)00452-8 · Cited by 298
Development of anti-p185HER2 immunoliposomes for cancer therapy.
Park, J. W., Hong, K., Carter, P., Asgari, H., Guo, L. Y., Keller, G. A., Wirth, C., Shalaby, R., Kotts, C., & Wood, W. I. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.5.1327 · Cited by 258
In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma.
de Menezes, D. E. L., Pilarski, L. M., & Allen, T. M. (1998) · PubMed · Cited by 257
Characterization of liposomal systems containing doxorubicin entrapped in response to pH gradients
Mayer, L. D., Tai, L. C. L., Bally, M. B., Mitilenes, G. N., Ginsberg, R. S., & Cullis, P. R. (1990) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(90)90091-2 · Cited by 245
Greenwald, R. B., Gilbert, C. W., Pendri, A., Conover, C. D., Xia, J., & Martinez, A. (1996) · Journal of Medicinal Chemistry · doi:10.1021/jm950475e · Cited by 223
Cited by
Liposome: classification, preparation, and applications
Akbarzadeh, A., Rezaei-Sadabady, R., Davaran, S., Joo, S. W., Zarghami, N., Hanifehpour, Y., Samiei, M., Kouhi, M., & Nejati-Koshki, K. (2013) · Nanoscale Research Letters · doi:10.1186/1556-276x-8-102 · Cited by 3,632
Nanoparticle PEGylation for Imaging and Therapy
Jokerst, J. V., Lobovkina, T., Zare, R. N., & Gambhir, S. S. (2011) · Nanomedicine · doi:10.2217/nnm.11.19 · Cited by 2,046
Reddy, L. H., Arias, J. L., Nicolas, J., & Couvreur, P. (2012) · Chemical Reviews · doi:10.1021/cr300068p · Cited by 2,010
New-Concept Chemotherapy by Nanoparticles of Biodegradable Polymers: Where Are We Now?
Feng, S.-S. (2006) · Nanomedicine · doi:10.2217/17435889.1.3.297 · Cited by 1,951
Active targeting schemes for nanoparticle systems in cancer therapeutics
Byrne, J. D., Betancourt, T., & Brannon-Peppas, L. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2008.08.005 · Cited by 1,731
Targeting nanoparticles to cancer
Wang, M., & Thanou, M. (2010) · Pharmacological Research · doi:10.1016/j.phrs.2010.03.005 · Cited by 931
Kim, M. S., Haney, M. J., Zhao, Y., Yuan, D., Deygen, I., Klyachko, N. L., Kabanov, A. V., & Batrakova, E. V. (2018) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2017.09.011 · Cited by 663
Nanomedicine for targeted cancer therapy: Towards the overcoming of drug resistance
Shapira, A., Livney, Y. D., Broxterman, H. J., & Assaraf, Y. G. (2011) · Drug Resistance Updates · doi:10.1016/j.drup.2011.01.003 · Cited by 504
Biodegradable calcium phosphate nanoparticle with lipid coating for systemic siRNA delivery
Li, J., Chen, Y.-C., Tseng, Y.-C., Mozumdar, S., & Huang, L. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2009.11.008 · Cited by 470
Self-citationLipid-based systemic delivery of siRNA
Tseng, Y.-C., Mozumdar, S., & Huang, L. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.03.003 · Cited by 463
Self-citationSong, W., Shen, L., Wang, Y., Liu, Q., Goodwin, T. J., Li, J., Dorosheva, O., Liu, T., Liu, R., & Huang, L. (2018) · Nature Communications · doi:10.1038/s41467-018-04605-x · Cited by 375
Self-citationTumor-targeted Delivery of siRNA by Self-assembled Nanoparticles
Li, S.-D., Chen, Y.-C., Hackett, M. J., & Huang, L. (2008) · Molecular Therapy · doi:10.1038/sj.mt.6300323 · Cited by 333
Self-citationLi, J., Yang, Y., & Huang, L. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.10.020 · Cited by 306
Self-citationHu, K., Miao, L., Goodwin, T. J., Li, J., Liu, Q., & Huang, L. (2017) · ACS Nano · doi:10.1021/acsnano.7b01522 · Cited by 292
Self-citationLi, S.-D., & Huang, L. (2006) · Molecular Pharmaceutics · doi:10.1021/mp060039w · Cited by 282
Self-citationAdvances in gene delivery through molecular design of cationic lipids
Bhattacharya, S., & Bajaj, A. (2009) · Chemical Communications · doi:10.1039/b900666b · Cited by 264
Nanodrug delivery in reversing multidrug resistance in cancer cells
Yergeri, M., Kapse-Mistry, S., Srivastava, R., & Govender, T. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00159 · Cited by 255
Phosphorescent Nanoscale Coordination Polymers as Contrast Agents for Optical Imaging
Liu, D., Huxford, R. C., & Lin, W. (2011) · Angewandte Chemie International Edition · doi:10.1002/anie.201008277 · Cited by 254
Nonviral methods for siRNA delivery
Gao, K., & Huang, L. (2009) · Molecular Pharmaceutics · doi:10.1021/mp800134q · Cited by 244
Self-citationHepatic macrophages act as a central hub for relaxin-mediated alleviation of liver fibrosis
Hu, M., Wang, Y., Liu, Z., Yu, Z., Guan, K., Liu, M., Wang, M., Tan, J., & Huang, L. (2021) · Nature Nanotechnology · doi:10.1038/s41565-020-00836-6 · Cited by 136
Self-citationTargeting Serous Epithelial Ovarian Cancer with Designer Zinc Finger Transcription Factors
Lara, H., Wang, Y., Beltran, A. S., Juárez-Moreno, K., Yuan, X., Kato, S., Leisewitz, A. V., Cuello Fredes, M., Licea, A. F., Connolly, D. C., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.360768 · Cited by 42
Self-citation
Metadata
- Authors
- Banerjee, R., Tyagi, P., Li, S., & Huang, L.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2004-06-30
- Volume
- 112
- Issue
- 4
- Pages
- 693-700
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W2065079114
- Cited by
- 274
- References
- 26
- FWCI
- 1.44
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.